Eli Samaha Sells 273,871 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 273,871 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00.
• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total value of $428,712.51.

Theravance Biopharma Stock Down 0.3%

TBPH opened at $16.93 on Friday. The stock has a market capitalization of $872.74 million, a price-to-earnings ratio of 7.70 and a beta of 0.17. The firm has a 50 day moving average price of $16.57 and a 200-day moving average price of $17.28. Theravance Biopharma, Inc. has a twelve month low of $10.82 and a twelve month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million for the quarter. As a group, analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday. TD Cowen raised their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. B. Riley Financial upped their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Weiss Ratings downgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. Finally, Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. One analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $21.40.

Institutional Trading of Theravance Biopharma

Institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Theravance Biopharma during the first quarter worth about $101,000. Jane Street Group LLC grew its stake in Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Creative Planning purchased a new stake in shares of Theravance Biopharma during the second quarter worth approximately $139,000. American Century Companies Inc. increased its position in shares of Theravance Biopharma by 6.8% in the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 5,794 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,789 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.